Go to:
Logótipo
Comuta visibilidade da coluna esquerda
Você está em: Start > Publications > View > The selective COX-2 inhibitor Etoricoxib reduces acute inflammatory markers in a model of neurogenic laryngitis but loses its efficacy with prolonged treatment
Publication

Publications

The selective COX-2 inhibitor Etoricoxib reduces acute inflammatory markers in a model of neurogenic laryngitis but loses its efficacy with prolonged treatment

Title
The selective COX-2 inhibitor Etoricoxib reduces acute inflammatory markers in a model of neurogenic laryngitis but loses its efficacy with prolonged treatment
Type
Article in International Scientific Journal
Year
2010
Authors
Lima Rodrigues, M
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Lamas, N
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Valle Fernandes, A
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Cruz, A
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. View Authenticus page Without ORCID
Vieira, A
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
oliveira, p
(Author)
ICBAS
View Personal Page You do not have permissions to view the institutional email. Search for Participant Publications View Authenticus page Without ORCID
Pedrosa, J
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. View Authenticus page Without ORCID
Reis, RM
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. View Authenticus page Without ORCID
Baltazar, F
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. View Authenticus page Without ORCID
Almeida, A
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. View Authenticus page Without ORCID
Journal
Title: Inflammation ResearchImported from Authenticus Search for Journal Publications
Vol. 59
Pages: 743-753
ISSN: 1023-3830
Publisher: Springer Nature
Other information
Authenticus ID: P-003-3EA
Abstract (EN): A randomised experimental study was used to evaluate the therapeutic effect of a selective cyclooxygenase-2 (COX-2) inhibitor in neurogenic laryngitis. Male Wistar Han rats were subjected to the nasogastric intubation model (NGI) of laryngitis for 1 and 2 weeks. The NGI animals were divided into three groups: (1) treated with COX-2 inhibitor Etoricoxib, (2) vehicle and (3) non-intubated animals. A fourth group of animals was submitted to NGI only. Laryngeal sections were immunostained for substance P (SP) and calcitonin gene-related peptide (CGRP) fibre-immunoreactivity (IR) and quantification of COX-2 positive cells through stereological analysis. The expression of COX-2, interleukins IL-1 beta, IL-6, IL-10 and tumour necrosis factor-alpha (TNF-alpha) was determined by quantitative real time QRT-PCR. Etoricoxib (6 mg/kg/day) was prepared in 0.9% sterile saline with 5% glucose (vehicle) and administered daily during 1 or 2 weeks. Treatment for 1 week with Etoricoxib attenuated the CGRP-IR fibre depletion, the COX-2-IR increased cell number and the TNF-alpha and COX-2 mRNA increased levels induced by NGI. Two weeks of treatment had no beneficial effect. Etoricoxib is effective in neurogenic laryngitis for limited periods of administration, indicating that selective COX-2 inhibitors should be evaluated in the future.
Language: English
Type (Professor's evaluation): Scientific
No. of pages: 11
Documents
We could not find any documents associated to the publication.
Related Publications

Of the same journal

Cancer- and cardiac-induced cachexia: Same fate through different inflammatory mediators? (2022)
Another Publication in an International Scientific Journal
Rita Nogueira-Ferreira; Fábio Sousa-Nunes; Adelino Leite-Moreira; Liliana Moreira-Costa; Rui Vitorino; Lúcio Lara Santos; Daniel Moreira-Gonçalves; Rita Ferreira
Bioactive compounds as potential angiotensin-converting enzyme II inhibitors against COVID-19: a scoping review (2022)
Another Publication in an International Scientific Journal
de Matos, PH; da Silva, TP; Mansano, AB; Gancedo, NC; Tonin, FS; Pelloso, FC; Petruco, MV; de Melo, EB; Fernandez-Llimos, F; Sanches, ACC; de Mello, JCP; Chierrito, D; Araujo, DCD
Inflammatory biomarkers in staging of chronic kidney disease: elevated TNFR2 levels accompanies renal function decline (2022)
Article in International Scientific Journal
Lousa, I; Belo, L; Valente, MJ; Rocha, S; Preguica, I; Rocha-Pereira, P; Beirao, I; Mira, F; Alves, R; Reis, F; Alice Santos Silva
Evaluation of urinary cysteinyl leukotrienes as biomarkers of severity and putative therapeutic targets in COVID-19 patients (2023)
Article in International Scientific Journal
Reina Couto, M; Roboredo Madeira, M; Pereira Terra, P; Silva Pereira, C; Martins, S; Teixeira Santos, L; Pinho, Dora; Dias, A; Cordeiro, G; Dias C; Sarmento A; Tavares, M; guimaraes, jt; Roncon-Albuquerque R Jr; Paiva, J-A; Albino Teixeira, A; Sousa, T
Recommend this page Top
Copyright 1996-2025 © Faculdade de Direito da Universidade do Porto  I Terms and Conditions  I Acessibility  I Index A-Z
Page created on: 2025-08-13 at 05:27:52 | Privacy Policy | Personal Data Protection Policy | Whistleblowing